Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808957 | 0.89 | ALDH1A1 (0.50) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL17424235 | 0.85 | ALDH1A1 (0.41) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL7039335 | 0.79 | CYP4F2 (0.40) | CYP4F2CYP4A11TSHRALDH1A1 | |
| SCHEMBL669239 | 0.78 | CYP4F2 (0.57) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL9938105 | 0.78 | ALDH1A1 (0.41) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL16282528 | 0.77 | CYP4F2 (0.38) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL4431871 | 0.76 | ALDH1A1 (0.39) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL9937333 | 0.76 | CES2 (0.43) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL18217931 | 0.75 | CYP4F2 (0.49) | CYP4F2CYP4A11TSHRALDH1A1THRB | |
| SCHEMBL12200870 | 0.75 | CYP4F2 (0.49) | CYP4F2CYP4A11TSHRALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696955-B2 | Drug-polymer conjugate | POLYACTIVA PTY LTD (AU) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11696955-B2 | Drug-polymer conjugate | PTGDR, PTGDR2, PTGER3 | CYP4F2 435/4885CYP4A11 419/4885TSHR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.